1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S.; Furuse, J.; Tak, W.; Masi, G.; Varela, M.; Kim, J.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
    Meeting Abstract

    Boerner, T.; Tin, A.; Vickers, A.; Harrington, C.; Janjigian, Y.; Ilson, D.; Wu, A.; Bott, M.; Isbell, J.; Park, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
    Meeting Abstract

    Cytryn, S.; Lumish, M.; Paroder, V.; Philemond, S.; Lewis, J.; Lyashchenko, S.; Janjigian, Y.; Pandit-Taskar, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Meeting Abstract

    Janjigian, Y.; Rha, S.; Oh, D.; Díez García, M.; van Laarhoven, H.; Chao, Y.; Di Bartolomeo, M.; Haj Mohammad, N.; Zhong, W.; Croydon, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
    Meeting Abstract

    Margalit, O.; Harmsen, W.; Shacham-Shmueli, E.; Voss, M.; Boursi, B.; Cohen, R.; Olswold, C.; Saltz, L.; Hurwitz, H.; Adams, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
    Meeting Abstract

    Hendifar, A.; Rosen, L.; McRee, A.; Cercek, A.; Basu-Mallick, A.; Spigel, D.; Tavazoie, S.; Rowinsky, E.; Szarek, M.; Gonsalves, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Meeting Abstract

    Tabernero, J.; Strickler, J.; Nakamura, Y.; Shitara, K.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Yoshino, T.; Siena, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study (daNIS-3) of the antieTGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
    Meeting Abstract

    Segal, N.; Rivera, F.; Tournigand, C.; Kasper, S.; Chen, Y.; Deshpande, P.; Messmann, R.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Ku, G.; Piha-Paul, S.; Gupta, M.; Oh, D.; Kim, Y.; Lee, J.; Rha, S.; Kang, Y.; Diez García, M.; Fleitas Kanonnikoff, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study (daNIS-2) of the antieTGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
    Meeting Abstract

    O'Reilly, E.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wainberg, Z.; Wang, L.; Gyambibi, N.; López, E.; Xu, K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save